{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:16:10Z","timestamp":1788419770026,"version":"build-2803163510"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Drug Deliv."],"abstract":"<jats:p>Efficient delivery of gene therapy vectors and regenerative cargo to the central nervous system (CNS) is limited by the hyaluronic acid (HA)-rich extracellular matrix (ECM). Adeno-associated virus (AAV) particles, mesenchymal stem cells (MSCs), multilineage-differentiating stress-enduring (MUSE) cells, and small extracellular vesicles (sEVs) must traverse the HA-rich ECM of the nasal submucosa, the perineural and perivascular compartments, and brain parenchyma to reach CNS targets. Dense ECM imposes viscosity, steric, and hydrodynamic barriers that limit tissue penetration, and perineuronal nets impose an additional HA-based barrier around subsets of neurons. Hyaluronidase enzymes transiently depolymerize HA, reducing tissue viscosity and increasing interstitial permeability through a well-defined, reversible mechanism. Recombinant human hyaluronidase PH20 (rHuPH20) is FDA-approved as a subcutaneous delivery adjunct, demonstrating that controlled ECM modulation is clinically feasible and safe. Preclinical studies demonstrate that hyaluronidase pretreatment enhances intranasal CNS delivery of AAV vectors and sEVs, with quantified improvements in olfactory bulb and cortical distribution. Intranasal MSC and MUSE cell delivery is similarly enhanced: 100 USP units of hyaluronidase applied 30\u00a0min before cell administration significantly increased MSC delivery to the olfactory bulb and total brain area in rodent models (p = 0.02). MUSE cells, which express sphingosine-1-phosphate receptor 2 (S1PR2) and home actively to sites of neuroinflammation via the S1P\u2013S1PR2 axis, achieve selective CNS distribution after intranasal administration in Parkinson\u2019s disease models, outperforming non-MUSE MSCs and restoring dopaminergic neuron markers and motor function. This narrative review synthesizes the mechanistic basis, evidence tiers, practical intranasal dosing and technique protocols, safety considerations, and translational knowledge gaps for hyaluronidase as a CNS delivery adjunct across viral gene therapy, non-viral platforms, gene-modified cell products, and sEV-based therapeutics. We distinguish established, off-label, and investigational applications, and provide practical guidance for clinicians developing hyaluronidase-augmented CNS programs.<\/jats:p>","DOI":"10.3389\/fddev.2026.1906950","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:41:20Z","timestamp":1788417680000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hyaluronidase-enhanced delivery in gene therapy and regenerative medicine for improved vector, cell, and cargo access"],"prefix":"10.3389","volume":"6","author":[{"given":"Patrick E.","family":"Sewell","sequence":"first","affiliation":[{"name":"Triple Helix Science","place":["Santa Ana, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"974666","DOI":"10.3389\/fphar.2022.974666","article-title":"Intranasal delivery: an attractive route for administration of nanoparticles to the brain","volume":"13","author":"Agrawal","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3390\/jcm15010279","article-title":"Hyaluronidase use in aesthetic medicine: formulations, safety, and clinical practice","volume":"15","author":"Arrigoni","year":"2025","journal-title":"J. Clin. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.3390\/ijms21124407","article-title":"Transport of extracellular vesicles across the blood\u2013brain barrier: brain pharmacokinetics and effects of inflammation","volume":"21","author":"Banks","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.1159\/isbn.978-3-318-07087-3","author":"Kang","year":"2022","journal-title":"ENHANZE\u00ae Drug Delivery Technology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"37462","DOI":"10.1021\/acsami.3c06909","article-title":"pH-sensitive biomimetic nanosystem based on large-pore mesoporous organosilica coated with hyaluronidase","volume":"15","author":"Chen","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"B9","doi-asserted-by":"publisher","first-page":"114474","DOI":"10.1016\/j.ejpb.2024.114474","article-title":"Hyaluronidase overcomes the extracellular matrix barrier to enhance local drug delivery","volume":"203","author":"Chen","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2217\/nnm-2020-0433","article-title":"Depolymerization of hyaluronan by PEGPH20 improves nanoparticle tumor penetration in a genetically engineered mouse model of pancreatic cancer","volume":"16","author":"Cheng","year":"2021","journal-title":"Nanomedicine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ejcb.2009.02.001","article-title":"Intranasal delivery of cells to the brain","volume":"88","author":"Danielyan","year":"2009","journal-title":"Eur. J. Cell Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1177\/1078155218817819","article-title":"Clinical considerations of hyaluronidase as an adjunct to subcutaneous rituximab injection","volume":"25","author":"de Lemos","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B15","doi-asserted-by":"publisher","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/pharmaceutics13010122","article-title":"Unlocking the power of exosomes for crossing biological barriers in drug delivery","volume":"13","author":"Elliott","year":"2021","journal-title":"Pharmaceutics"},{"key":"B17","volume-title":"Guideline on the Quality, Non-clinical and Clinical Aspects of Gene Therapy Medicinal Products (EMA\/CAT\/80183\/2014)","year":"2018"},{"key":"B18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s43556-025-00299-y","article-title":"Hyaluronidase: structure, mechanism of action, diseases and therapeutic applications","volume":"6","author":"Feng","year":"2025","journal-title":"Mol. Biomed."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e112297","DOI":"10.1371\/journal.pone.0112297","article-title":"Hyaluronidase modulates inflammatory response and accelerates the cutaneous wound healing","volume":"9","author":"Fronza","year":"2014","journal-title":"PLoS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1517\/17425247.4.4.427","article-title":"Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration","volume":"4","author":"Frost","year":"2007","journal-title":"Expert Opin. Drug Deliv."},{"key":"B23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMra1706910","article-title":"Gene therapy","volume":"381","author":"High","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1158\/1078-0432.CCR-15-2010","article-title":"Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer","volume":"22","author":"Hingorani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"8639","DOI":"10.1073\/pnas.0911647107","article-title":"Unique multipotent cells in adult human mesenchymal cell populations","volume":"107","author":"Kuroda","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B26","doi-asserted-by":"publisher","first-page":"S347","DOI":"10.1097\/DSS.0000000000000555","article-title":"Hyaluronidase caveats in treating filler complications","volume":"41","author":"Landau","year":"2015","journal-title":"Dermatol. Surg."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.3390\/pharmaceutics15112574","article-title":"Rapid and widespread distribution of intranasal small extracellular vesicles to the central nervous system","volume":"15","author":"Lee","year":"2023","journal-title":"Pharmaceutics"},{"key":"B28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4155\/tde.14.101","article-title":"Immunogenicity of PH20 hyaluronidase in subcutaneous drug administration","volume":"6","author":"Loch","year":"2015","journal-title":"Ther. Deliv."},{"key":"B29","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3762\/bjnano.11.72","article-title":"Key for crossing the BBB with nanoparticles: the rational design","volume":"11","author":"Lombardo","year":"2020","journal-title":"Beilstein J. Nanotechnol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1186\/s12967-025-07401-6","article-title":"Intranasally administered muse cells attenuate neurodegeneration in Parkinson's disease","volume":"23","author":"Lu","year":"2025","journal-title":"J. Transl. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/jnc.15915","article-title":"Hyaluronan hydrates and compartmentalises the CNS\/PNS extracellular matrix","volume":"166","author":"Melrose","year":"2023","journal-title":"J. Neurochem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jconrel.2024.07.062","article-title":"The safety of recombinant human hyaluronidase PH20 in nonclinical models: an overview of toxicology, pharmacology, and impact of anti-PH20 antibodies","volume":"374","author":"Nolan","year":"2024","journal-title":"J. Control. Release"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1080\/14740338.2016.1202100","article-title":"Pooled safety analysis of subcutaneous trastuzumab with hyaluronidase","volume":"15","author":"Pivot","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1097\/DSS.0000000000002345","article-title":"Ultrasound-guided hyaluronidase injection in managing hyaluronic acid filler-related complications","volume":"46","author":"Schelke","year":"2020","journal-title":"Dermatol. Surg."},{"key":"B37","article-title":"HYLENEX recombinant (hyaluronidase human injection)","volume-title":"NDA 021-859","year":"2005"},{"key":"B38","volume-title":"Current Good Manufacturing Practice for Combination Products. Guidance for Industry","year":"2017"},{"key":"B40","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3389\/fnmol.2017.00226","article-title":"Intranasal adeno-associated virus mediated gene delivery to the central nervous system","volume":"11","author":"Watson","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/978-981-13-7709-9_12","article-title":"Clinical applications of hyaluronidase","volume":"1148","author":"Weber","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e12404","DOI":"10.1002\/jev2.12404","article-title":"Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches","volume":"13","author":"Welsh","year":"2024","journal-title":"J. Extracell. Vesicles"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1038\/s41380-022-01634-3","article-title":"The extracellular matrix and perineuronal nets in memory","volume":"27","author":"Wen","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1177\/0091270012436560","article-title":"Comparison of subcutaneous and intravenous administration of trastuzumab","volume":"53","author":"Wynne","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/pharmaceutics17020234","article-title":"Recent advances in nose-to-brain gene delivery for central nervous system disorders","volume":"17","author":"Yang","year":"2025","journal-title":"Pharmaceutics"},{"key":"B48","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.omtm.2023.03.009","article-title":"Formulation and CMC considerations for combination products in gene therapy","volume":"29","author":"Yao","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jconrel.2023.11.015","article-title":"Small extracellular vesicles facilitate stroke recovery through enhanced perivascular delivery after intranasal administration","volume":"365","author":"Zhang","year":"2024","journal-title":"J. Control. Release"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1192257","DOI":"10.3389\/fmats.2023.1192257","article-title":"Hyaluronic acid-based hydrogels as exosome delivery systems in bone regeneration","volume":"10","author":"Zhao","year":"2023","journal-title":"Front. Mater."}],"container-title":["Frontiers in Drug Delivery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fddev.2026.1906950\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:41:22Z","timestamp":1788417682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fddev.2026.1906950\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":39,"alternative-id":["10.3389\/fddev.2026.1906950"],"URL":"https:\/\/doi.org\/10.3389\/fddev.2026.1906950","relation":{},"ISSN":["2674-0850"],"issn-type":[{"value":"2674-0850","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1906950"}}